U.S. FDA Approves PIMJETMI (Pimicotinib) for Symptomatic Tenosynovial Giant Cell Tumor

The U.S. Food and Drug Administration (FDA) has approved PIMJETMI® (pimicotinib), a small-molecule colony-stimulating factor 1 receptor (CSF-1R) inhibitor, as a systemic treatment for adults with symptomatic tenosynovial giant cell tumor (TGCT) where surgical resection could lead to worsening functional limitation or severe morbidity. This marks the fourth marketing approval for pimicotinib globally, following approvals in China, Canada, and Switzerland.